Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

Summary

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)

Timeline

Start

2025-02-06

Primary completion

2027-05

Completion

2028-01

Drugs

Indications